Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes
Clinical trial NCT05065879 · COMPLETED
Trial details
- NCT number
- NCT05065879
- Sponsor
- China National Biotec Group Company Limited
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-05
- Primary completion
- 2022-01-05
- Enrollment
- 1440
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.